News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Medsafe, PHARMAC With Different Roles In Medicine

Medsafe, PHARMAC With Different Roles In Medicine Assessment

New Zealand has two agencies that assess medicines – Medsafe, the regulator, and PHARMAC, the funder. Both have separate and distinct roles and are independent of each other.

Medsafe is part of the Ministry of Health. Further information about Medsafe can be found at http://www.medsafe.govt.nz. In general terms, however, all medicines must be approved by Medsafe before they can be sold in New Zealand. Medsafe applies internationally agreed standards of quality, safety and efficacy to data submitted by the manufacturer of a medicine before making a decision to approve or reject a medicine.

Medsafe utilises an independent advisory committee called the Medicines Assessment Advisory Committee, to advise it on applications to sell new medicines in New Zealand.

This committee evaluates data from clinical trials and testing programmes to determine the: Quality – is the manufacturing of the medicine of sufficient standard? Safety – is the medicine safe for patients and users? Efficacy – does the medicine or device work for patients with a specific medical condition?

All medicines approved by Medsafe are available for New Zealand patients. However, not all medicines are subsidised by the Government. Which ones are, and any criteria for access, is determined by PHARMAC.

In making its assessment, PHARMAC looks at both the clinical evidence of the drug and the cost of any benefits it might provide. A committee made up of clinicians with expertise in examining clinical evidence – the Pharmacology and Therapeutics Advisory Committee (PTAC) – makes recommendations to PHARMAC.

Both PHARMAC and Medsafe receive large volumes of information about new pharmaceuticals. This includes information from suppliers, literature sourced from medical journals, or other information.

In addition to PTAC’s clinical advice, PHARMAC does its own economic analysis of the product. This helps PHARMAC decide what priority for funding to give the medicine.

In essence, PHARMAC asks whether the drug in question is better than those that are already subsidised, in other words what its “relative efficacy” is. Often there are claims that a new drug is better than an older drug. PHARMAC uses the evidence to examine those claims closely to decide if new therapies really do offer an advantage over other ones.

PHARMAC uses nine decision criteria to decide what priority to give pharmaceuticals for new funding.

The health needs of all eligible people;

The particular health needs of Maori and Pacific peoples;

The availability and suitability of existing medicines, therapeutic medical devices and related products and related things;

The clinical benefits and risks of pharmaceuticals;

The cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;

The budgetary impact (in terms of the pharmaceutical budget and the Government’s overall health budget) of any changes to the Schedule;

The direct cost to health service users;

The Government’s priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC’s Funding Agreement, or elsewhere; and

Such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such “other criteria” into account.

New Zealand differs from other countries in having an agreed pharmaceutical budget, which in the 2006 financial year is set at $582.6 million. Any new spending has to fit within that budget, while still enabling all the drugs that are already funded to continue being available.

For more information go to http://www.pharmac.govt.nz.

ENDS

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Howard Davis Article: A Musical Axis - Brahms, Wagner, Sibelius

Brahms' warm and exquisitely subtle Symphony No. 3 in F major, Wagner's irrepressibly sentimental symphonic poem Siegfried Idyll, and Sibelius' chilling and immensely challenging Violin Concerto in D minor exemplify distinct stages of development in a tangled and convoluted series of skirmishes that came to define subsequent disputes about the nature of post-Romantic orchestral writing well into the following century. More>>

ALSO:

Scoop Review Of Books: A Pale Ghost Writer

Reviewed by Ruth Brassington, Richard Flanagan's new novel is about a novelist hastily ghost-writing the biography of a crook about to go to trial. The reader is kept on a cliff-edge, as the narrator tries to get blood out of his stone man. More>>

Negotiations Begin: Equal Conditions For Men & Women In Professional Football

The trade union representing New Zealand's professional footballers has initiated bargaining for an agreement securing equal terms and conditions for men and women. If negotiated, it will be the first agreement of its kind in the world. More>>

ALSO:


New Zealand Wars Commemoration: Witi Ihimaera's Sleeps Standing Moetū

The second of several articles to mark Rā Maumahara, remembering the New Zealand Land Wars. The first was a Q&A with Vincent O’Malley, author of The Great War for New Zealand: Waikato 1800–2000. More>>

ALSO:


Howard Davis Review: Conflict & Resistance - Ria Hall's Rules of Engagement

From the aftermath of war through colonisation to her own personal convictions, Hall's new CD addresses current issues and social problems on multiple levels, confirming her position as a polemical and preeminent voice on the indigenous NZ music scene. More>>

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland